CA125 and immunoinflammatory activity in acute heart failure (original) (raw)
Related papers
Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure
Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē
Increased serum levels of carbohydrate antigen 125 (CA125), a tumor marker associated with ovarian cancer, have also been reported in other malignant and non-malignant diseases. We assessed the correlation of the CA125 serum levels with the severity of congestive heart failure (CHF) and investigated their potential prognostic value in relation to major cardiovascular events. CA125 levels were measured in 95 male patients aged 70+/-10 years, admitted for decompensated CHF. The patients were divided into three groups, according to their New York Heart Association (NYHA) functional class. Group A contained 23 patients in NYHA IV, group B 34 patients in NYHA III, and group C 38 patients in NYHA I-II. The patients were also divided into two groups according to their CA125 value on admission. Group 1 included 45 patients with normal CA125 levels and group 2 50 patients with elevated CA125. All patients were followed for 15+/-8.5 months and the major cardiovascular events (death and re-hos...
Case Reports in Cardiology
Despite the recent, remarkable achievements in cardiology, heart failure (HF) remains a major public health problem due to its increasing prevalence, frequent hospitalizations, and significant mortality. Humoral biomarkers in HF are capable to reflect different aspects of the cardiac morpho-functional changes and the related pathophysiological processes and could have important diagnostic, prognostic, and therapeutical roles. CA-125 is a well-known tumor marker (mainly for ovarian cancer), and also a useful, but less applied cardiac biomarker. Practical aspects, possible pitfalls related with increased CA-125 levels are illustrated by two cases, both with HF, with the biomarker determined for other reasons and having high levels in the context of the cardiac decompensation. The paper presents a short review of the main biochemical, pathophysiological, and clinical data linked to CA-125, with special accent on its utility in patients with HF.
Cardiac Failure Review, 2021
Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of C...
Long-Term Prognostic Value of CA 125 Serum Levels in Mild to Moderate Heart Failure Patients
Journal of Cardiac Failure, 2012
Plasma levels of tumor marker carbohydrate 125 antigen (CA 125) have been found elevated among patients with advanced heart failure (HF). We evaluated the prognostic value of CA125 in a population of patients with mild to moderate HF. Serum levels of CA 125 were obtained in 102 patients with mild to moderate HF from idiopathic (48%) or ischemic (52%) dilated cardiomyopathy (age 64 ± 10.4 years, left ventricular ejection fraction: 34.4 ± 8.5%), under optimized medical therapy. During follow-up (43 ± 15 months), 16 (15.7%) cardiovascular deaths and 23 (22.5%) cardiovascular deaths + HF hospitalizations were recorded. Considering cardiac death, comparison of Kaplan-Meier survival curves by the log-rank test showed that patients with CA 125 levels higher than the cut-off value (30 U/mL) had a worse survival (P < .0001). This was observed also when considering cardiovascular death+ HF hospitalizations as the secondary end point (P = .0003). Event-free survival was assessed by Kaplan-Meier method and log-rank test. Multivariable Cox proportional stepwise hazards regression analysis was performed and showed that CA 125 and systolic pulmonary artery pressure (sPAP) were significantly associated with the risk of cardiovascular deaths + HF hospitalizations (HR 1.01, 95% CI 1.02-1.06, and HR 1.07, 95% CI 1.02-1.1, P < .001, respectively). In mild-to-moderate HF patients under optimized therapy, higher plasma CA 125 levels are an effective long-term prognostic marker in forecasting cardiovascular events and HF hospitalization and may contribute to a better risk stratification.
Echocardiography, 2008
Plasma levels of the tumoral carbohydrate 125 antigen marker (CA 125) have been found elevated in patients with heart failure. We measured the plasma levels of CA 125 and other tumoral markers in a group of patients with chronic heart failure and we found a correlation between the serum levels with some left ventricular parameters calculated with transthoracic echocardiography (ETT). We studied 200 patients, 159 males and 41 females, suffering from idiopathic or ischemic cardiomyopathy, 126 of them in NYHA class II, 39 in class III, and 35 in NYHA class IV. CA 125 levels were correlated with Doppler mitral flow E-wave, E/A ratio, deceleration time (DT), isovolumetric relaxation time (IVRT), and myocardial performance index (MPI) (r = 0.38, 0.35, -0.46, -0.48, and 0.35, respectively, all with P < 0.05). Multiple regression analysis found the following parameters to be independently correlated to CA 125: long- and short-axis diameter, MPI, IVRT, and E/A. Plasma CA 125 levels were raised in patients with chronic heart failure and were related to clinical condition and to diastolic and systolic function parameters of the left ventricle. CA 125 could be used as an additional, noninvasive, easily determinable, and low-cost marker of the clinical condition of patients affected by heart failure.